Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome

Blood

Volumn 123, Issue 7, 2014, Pages 1090-1097

  Kolyada, Alexey ^a   Porter, Andrew ^a   Beglova, Natalia ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A1 A1; ANTICOAGULANT AGENT; APOLIPOPROTEIN E RECEPTOR 2; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; RECEPTOR; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 8; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; CELL SURFACE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG STABILITY; FEMALE; IN VIVO STUDY; LUPUS VULGARIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOSIS; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DISEASE MODEL; IMMUNOLOGY; PATHOLOGY; TIME;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOGLOBULIN G; LDL-RECEPTOR RELATED PROTEINS; MALE; MICE; MICE, INBRED BALB C; THROMBOSIS; TIME FACTORS;

EID: 84897834063     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-08-520882     Document Type: Article

References (58)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
2. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033-1044.
3. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med. 2011;270(2):110-122.
4. Bertero MT, Bazzan M, Carignola R, et al Antiphospholipid Piedmont Consortium. Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile. Lupus. 2012;21(7):806-809.
5. Cervera R, Piette JC, Font J, et al Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027. (Pubitemid 34303815)
6. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242.
7. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714- 4718.
8. de Groot PG, Meijers JC. β(2)-Glycoprotein I: evolution, structure and function. J Thromb Haemost. 2011;9(7):1275-1284.
9. De Groot PG, Meijers JC, Urbanus RT. Recent developments in our understanding of the antiphospholipid syndrome. Int J Lab Hematol. 2012;34(3):223-231.
10. de Groot PG, Urbanus RT. The significance of autoantibodies against β2-glycoprotein I. Blood. 2012;120(2):266-274.
11. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004;104(12):3598-3602. (Pubitemid 39564433)
12. Giannakopoulos B, Mirarabshahi P, Krilis SA. New insights into the biology and pathobiology of beta2-glycoprotein I. Curr Rheumatol Rep. 2011;13(1):90-95.
13. Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost. 1992;67(6):649-653.
14. Miyakis S, Robertson SA, Krilis SA. Beta-2 glycoprotein I and its role in antiphospholipid syndrome-lessons from knockout mice. Clin Immunol. 2004;112(2):136-143. (Pubitemid 38881478)
15. Sheng Y, Reddel SW, Herzog H, et al. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem. 2001;276(17):13817-13821.
16. Yasuda S, Tsutsumi A, Chiba H, et al. beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis. 2000;152(2):337-346.
17. Arad A, Proulle V, Furie RA, Furie BC, Furie B. β2-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 2011;117(12):3453-3459.
18. Jankowski M, Vreys I, Wittevrongel C, et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood. 2003;101(1):157-162. (Pubitemid 36025902)
19. Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT, et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood. 2011;117(4):1408-1414.
20. Harper BE, Wills R, Pierangeli SS. Pathophysiological mechanisms in antiphospholipid syndrome. Int J Clin Rheumtol. 2011;6(2):157-171.
21. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood. 2012;119(3):884-893.
22. Pennings MT, Derksen RH, van Lummel M, et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost. 2007;5(2):369-377. (Pubitemid 46139463)
23. Pennings MT, van Lummel M, Derksen RH, et al. Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost. 2006;4(8):1680-1690. (Pubitemid 44144793)
24. Ramesh S, Morrell CN, Tarango C, et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via b2GPI and apoER2. J Clin Invest. 2011;121(1):120-131.
25. Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006;54(8):2558-2567. (Pubitemid 44205017)
26. Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost. 2008;6(8):1405-1412. (Pubitemid 352016322)
27. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009;114(14):3074-3083.
28. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007;66(10):1327-1333. (Pubitemid 47492476)
29. Pennings MT, Derksen RH, Urbanus RT, Tekelenburg WL, Hemrika W, de Groot PG. Platelets express three different splice variants of ApoER2 that are all involved in signaling. J Thromb Haemost. 2007;5(7):1538-1544. (Pubitemid 46965385)
30. Kolyada A, Lee CJ, De Biasio A, Beglova N. A novel dimeric inhibitor targeting Beta2GPI in Beta2GPI/antibody complexes implicated in antiphospholipid syndrome. PLoS ONE. 2010;5(12):e15345.
31. Lee CJ, De Biasio A, Beglova N. Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids. Structure. 2010;18(3):366-376.
32. Lin F, Murphy R, White B, et al. Circulating levels of beta2-glycoprotein I in thrombotic disorders and in inflammation. Lupus. 2006;15(2):87-93. (Pubitemid 43345333)
33. Cugno M, Borghi MO, Lonati LM, et al. Patients with antiphospholipid syndrome display endothelial perturbation. J Autoimmun. 2010;34(2):105-110.
34. Kaplanski G, Cacoub P, Farnarier C, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum. 2000;43(1):55-64. (Pubitemid 30368213)
35. Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res. 2006;118(4):455-461. (Pubitemid 44308637)
36. Ferro D, Pittoni V, Quintarelli C, et al. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation. 1997;95(6):1425-1432. (Pubitemid 27142799)
37. Soltesz P, Der H, Veres K, et al. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford). 2008;47(11):1628-1634.
38. Akkerman A, Huang W, Wang X, et al. CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW/BXSB mice. Autoimmunity. 2004;37(6-7):445-451. (Pubitemid 40123413)
39. Hashimoto Y, Kawamura M, Ichikawa K, et al. Anticardiolipin antibodies in NZW x BXSB F1 mice. A model of antiphospholipid syndrome. J Immunol. 1992;149(3):1063-1068.
40. Yoshida H, Fujiwara H, Fujiwara T, Ikehara S, Hamashima Y. Quantitative analysis of myocardial infarction in (NZW x BXSB)F1 hybrid mice with systemic lupus erythematosus and small coronary artery disease. Am J Pathol. 1987;129(3):477-485. (Pubitemid 18029990)
41. Hang LM, Izui S, Dixon FJ. (NZW x BXSB)F1 hybrid. A model of acute lupus and coronary vascular disease with myocardial infarction. J Exp Med. 1981;154(1):216-221. (Pubitemid 11079819)
42. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest. 2007;117(4):953-960. (Pubitemid 46556751)
43. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8(10):1175-1181.
44. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003;197(11):1585- 1598. (Pubitemid 36682554)
45. van Lummel M, Pennings MT, Derksen RH, et al. The binding site in beta2-glycoprotein I for ApoER29 on platelets is located in domain V. J Biol Chem. 2005;280(44):36729-36736. (Pubitemid 41587752)
46. Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010;19(4):460-469.
47. Kahn P, Ramanujam M, Bethunaickan R, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum. 2008;58(9):2824-2834.
48. Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther. 2002;300(3):729-735. (Pubitemid 34164973)
49. Erkan D. Lupus and thrombosis. J Rheumatol. 2006;33(9):1715-1717. (Pubitemid 44373198)
50. Korschineck I, Ziegler S, Breuss J, et al. Identification of a novel exon in apolipoprotein E receptor 2 leading to alternatively spliced mRNAs found in cells of the vascular wall but not in neuronal tissue. J Biol Chem. 2001;276(16):13192-13197.
51. May P, Herz J, Bock HH. Molecular mechanisms of lipoprotein receptor signalling. Cell Mol Life Sci. 2005;62(19-20):2325-2338. (Pubitemid 41500548)
52. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 1992;269(3):375-382.
53. Yang XV, Banerjee Y, Fernández JA, et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci USA. 2009;106(1):274-279.
54. Blacklow SC. Versatility in ligand recognition by LDL receptor family proteins: advances and frontiers. Curr Opin Struct Biol. 2007;17(4):419-426. (Pubitemid 47451775)
55. Fisher C, Beglova N, Blacklow SC. Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors. Mol Cell. 2006;22(2):277-283.
56. Russell DW, Brown MS, Goldstein JL. Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins. J Biol Chem. 1989;264(36):21682-21688. (Pubitemid 20028736)
57. Yamamoto T, Ryan RO. Domain swapping reveals that low density lipoprotein (LDL) type A repeat order affects ligand binding to the LDL receptor. J Biol Chem. 2009;284(20):13396-13400.
58. Jensen JK, Dolmer K, Gettins PG. Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1. J Biol Chem. 2009;284(27):17989-17997.